In a clinical study, although not directly against cataract, silybin improved the peripheral nerve conduction velocity and was reported as an effective aldose reductase inhibitor that can improve the disorder of polyol pathway in non-insulin dependent diabetes patients and prevent chronic complications of diabetes (Zhang et al., 1995) like cataract. Here, AKR1B1 is linked to type 1 diabetes mellitus.